Literature DB >> 8986269

Bronchopulmonary-foregut malformations: a continuum of paracrine hamartomas?

B G Kousseff1, E Gilbert-Barness, D Debich-Spicer.   

Abstract

The bronchopulmonary-foregut malformations (BPFM) are usually sporadic, solitary cystic hamartomas involving conducting airways, arteries, venous drainage, and lung parenchyma. Transitional, compound hamartomas exist, and only their morphology is well-known. Between 1984-1994 we encountered and studied 10 unrelated patients and a stillborn infant with BPFM (out of 24,000 families). Ten were diagnosed in utero and one at birth as having congenital cystic adenomatoid malformation of the lung (CCAML). Postnatally, two diagnoses (20%) were corrected to bronchogenic cyst (BC) and diaphragmatic hernia, respectively. Bilateral lung involvement was present in 1 patient, and in 2 there was a considerable macroscopic regression of the hamartoma. Histologic studies of the six resected CCAML confirmed the diagnosis and implied dysregulated paracrine growth with its cellular and extracellular growth factors, protooncogenes, oncogenes, cytokines, cell-adhesive molecules, and receptors of these regulatory peptides, and their complex interactions as developmental morphogens in time and space.

Entities:  

Mesh:

Year:  1997        PMID: 8986269     DOI: 10.1002/(sici)1096-8628(19970110)68:1<12::aid-ajmg3>3.0.co;2-#

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  2 in total

1.  Antenatally diagnosed congenital cystic adenomatoid malformations (CCAM): Research Review.

Authors:  Fosca Antonia Francesca Di Prima; Adriano Bellia; Genny Inclimona; Francesco Grasso; Maria Teresa; Meli Nazario Cassaro
Journal:  J Prenat Med       Date:  2012-04

2.  Aberrant cell adhesion molecule expression in human bronchopulmonary sequestration and congenital cystic adenomatoid malformation.

Authors:  Maryann V Volpe; Eunice Chung; Jason P Ulm; Brian F Gilchrist; Steven Ralston; Karen T Wang; Heber C Nielsen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-01       Impact factor: 5.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.